Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib
Lung Cancer · 2023
DOI: 10.1016/j.lungcan.2023.02.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung Cancer, 2023. Verfasst von Emily Miao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, United States; Albert Einstein College of Medicine, Bro…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Highly effective brain-penetrant ALK-targeted tyrosine kinase inhibitors (TKIs) have been developed for the management of NSCLC patients with brain metastases (BM). Local therapy (LT) such as SRS or therapeutic craniotomy is increasingly being deferred for such patients. Herein we report detailed patient- and lesion-level intracranial outcomes and co-mutational genomic profiles from a cohort of NSCLC patients with BM treated with alectinib, with or without LT. METHODS: We retrospectively reviewed ALK fusion-positive NSCLC patients with BMs who received alectinib at the diagnosis of BM from 1/2012 and 5/2021. Outcome variables included intracranial progression-free survival (iPFS), overall survival (OS), duration of TKI therapy, and CNS response rates. Genomic characteristics from tumor specimens were assessed with MSK-IMPACT, a next-generation sequencing (NGS)-based genomic profiling assay. RESULTS: A total of 38 patients with 114 CNS lesions were included. Twelve of these patients also received contemporaneous LT (SRS, WBRT, or surgical resection). Maximal BM diameter in the TKI + LT group was greater (p < 0.003) but despite this difference, iPFS (TKI only, HR 1.21, 95 % CI 0.51-2.89; p = 0.66) and OS (TKI only, HR 5.99, 95 % CI 0.77-46.6; p = 0.052) were similar between groups and trended towards more favorable outcomes with the addition of LT. SMARCA4 co-alterations were associated with inferior OS (HR 8.76, 1.74-44.2; p = 0.009). CONCLUSIONS: Our study demonstrated that patients with ALK fusion-positive NSCLC treated with TKI + LT had larger BM and higher likelihood of pre-treatment neurologic symptoms. Despite these differences, iPFS was similar between groups. Results should be interpreted with caution as our study was limited by an underpowered sample size. SMARCA4 co-alterations were associated with inferior OS and these findings warrant further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, United States; Albert Einstein College of Medicine, Bronx, NY, United States.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, United States; Biomarker Development Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
- Memorial Sloan Kettering Cancer Center, New York, New York, United States.
- Memorial Sloan Kettering Cancer Center, New York, New York, United States; Biomarker Development Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Miao, E., Eichholz, J. E., Lebow, E. S., Flynn, J., Zhang, Z., Walch, H., Hubbeling, H., Beal, K., Moss, N. S., Yu, K. K., Meng, A., Kelly, D. W., Gomez, D. R., Li, B. T., Rimner, A., Schultz, N., Drilon, A., Imber, B. S., & Pike, L. R. G. (2023). Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib. Lung Cancer. https://doi.org/10.1016/j.lungcan.2023.02.005
Vancouver
Miao E, Eichholz JE, Lebow ES, Flynn J, Zhang Z, Walch H, et al. Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib. Lung Cancer. 2023. doi:10.1016/j.lungcan.2023.02.005
BibTeX
@article{Miao2023,
author = {Miao, Emily and Eichholz, Jordan E and Lebow, Emily S and Flynn, Jessica and Zhang, Zhigang and Walch, Henry and Hubbeling, Harper and Beal, Kathryn and Moss, Nelson S and Yu, Kenny K and Meng, Alicia and Kelly, Daniel W and Gomez, Daniel R and Li, Bob T and Rimner, Andreas and Schultz, Nikolaus and Drilon, Alexander and Imber, Brandon S and Pike, Luke R G},
title = {Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib},
journal = {Lung Cancer},
year = {2023},
doi = {10.1016/j.lungcan.2023.02.005}
}
EUVIMED